<DOC>
	<DOCNO>NCT02752919</DOCNO>
	<brief_summary>The study involve single dose galunisertib take mouth Japanese participant non-Japanese participant . The study evaluate relationship effect study drug electrical activity heart , measure electrocardiogram ( ECG ) much study drug get blood stream long take body remove . Ths study last 42 day participant .</brief_summary>
	<brief_title>Study Galunisertib Healthy Participants</brief_title>
	<detailed_description />
	<criteria>Are overtly healthy male female Japanese nonJapanese participant , determine medical history physical examination . Male participant : Must agree use reliable method birth control 12 week receive dose study drug , OR least 6 week postvasectomy documentation spermfree ejaculate . Female participant : Women childbearing potential may participate , include : Infertile due surgical sterilization ; Postmenopausal . All female participant must test negative pregnancy screen . Have body mass index ( BMI ) 18.5 32.0 kilogram per meter square ( kg/mÂ² ) , inclusive screening . Have clinical laboratory test result within normal reference range . Are able willing give sign informed consent . Have participate , within last 3 month , clinical trial involve Investigational Product ( IP ) . If previous IP long halflife , 3 month pass . Have know allergy galunisertibrelated compound component formulation , history significant atopy . Have personal family history long QT syndrome , heart failure , hypokalemia , sudden death . Have personal history unexplained syncope within last year . Have abnormality 12lead electrocardiogram ( ECG ) , opinion investigator , increase risk associate participate study affect confound correct QT ( QTc ) analysis ( ECG waveform morphology rhythm incompatible reliable measurement ECG interval ) , QTcF great ( &gt; ) 450 millisecond ( msec ) . Have abnormal blood pressure determine investigator . Have history presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take IP ; interfere interpretation data . Have serum magnesium potassium value outside normal reference range . Show evidence human immunodeficiency virus ( HIV ) infection , hepatitis C hepatitis B . Intend use overthecounter prescription medication ( include herbal medication ) within 14 day prior dose . Have donate blood 500 milliliter ( mL ) within last month Have average weekly alcohol intake exceed 21 unit per week ( male ) 14 unit per week ( female ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>